

NPY2R Antagonist

BII0246

Table of contents

Summary	2
Chemical Structure.....	2
Highlights.....	3
Target information.....	3
<i>In vitro</i> activity.....	3
<i>In vitro</i> DMPK and CMC parameters	4
<i>In vivo</i> pharmacology	5
Negative control.....	5
Selectivity.....	6
Reference molecules	6
Supplementary data	6
References.....	6

Summary

BIIE0246 is a highly potent, non-peptide, competitive neuropeptide Y (NPY) 2 receptor selective antagonist. A higher affinity analogue is available as a negative control.

Chemical Structure




Figure 1: 2D structure of BIIE0246, a non-peptide NPY2R antagonist.




Figure 2: 3D structure of BIIE0246, a non-peptide NPY2R antagonist.

Highlights

Since its introduction in 1999, BIIE0246 became the gold standard as pharmacological tool for the *in vitro* and *in vivo* study of Y2 receptor mediated effects. Its use has been documented in over 100+ scientific publications. It is offered together with its negative control, BIIE0212, a close analogue with 400-fold lower affinity towards the Y2 receptor than BIIE0246.

Target information

The neuropeptide Y2 receptor (Y2R) is a member of the neuropeptide Y (NPY) receptor family which in humans consists of the four rhodopsin-like (class A) GPCRs: Y1, Y2, Y4, and Y5.

NPY receptors are activated by a family of structurally related tyrosine-rich polypeptides, namely NPY, PYY (peptide tyrosine-tyrosine) and PP (pancreatic polypeptide) having a common length of 36 amino acids and an amidated C-terminus.

Y2 receptors are expressed in both the peripheral and central nervous system where they predominantly are located on presynaptic neurons. Brain regions with high expression levels of Y2 receptors are hippocampus, thalamus, hypothalamus and amygdala.

Y2 receptors are involved in the modulation of various (patho-) physiological processes including memory retention, anxiety, arousal, alcohol consumption and energy homeostasis. In particular, the appetite suppressant effect elicited by the activation of Y2 receptors expressed in the arcuate nucleus of the hypothalamus attracted considerable attention.

Recently, Beck-Sickinger et al. proposed a structural model for the binding mode of BIIE0246 in the Y2R binding site based on mutagenesis data and computational docking².

In vitro activity

BIIE0246 displaced radiolabelled neuropeptide Y from NPY2R sites on SMS-KAN cells expressing the hY2R, with an IC_{50} of 3.3 nM¹. In addition, BIIE0246 displayed an IC_{50} of 7.5 nM for the displacement of [¹²⁵I]-NPY from Y2R binding sites in preparations from rabbit kidney³.

The antagonistic properties of BIIE0246 were demonstrated by a concentration dependent right shift for the dose-response curve of the endogenous agonist NPY in the rat *vas deferens* assay – a functional bioassay for the Y2 receptor^{1,4}.

The low nanomolar binding affinity as well as the antagonistic potency of BIIE0246 was confirmed in several different cellular and tissue/isolated organ-based assays reported in various scientific papers⁵⁻⁹.

PROBE NAME / NEGATIVE CONTROL	BIIE0246	BIIE0212
MW [Da, free base] ^a	896.1	665.9
Radioligand binding hY2R (IC ₅₀) [nM] ^b	3.3	n.a.
Radioligand binding rabbit Y2R (IC ₅₀) [nM] ^c	7.5	3300
Radioligand binding rY1R IC ₅₀) [nM] ^d	>10,000	n.a.
Radioligand binding rY2R IC ₅₀) [nM] ^d	15	n.a.
Radioligand binding rY4R IC ₅₀) [nM] ^d	>10,000	n.a.
Radioligand binding rY5R IC ₅₀) [nM] ^d	>10,000	n.a.
Y2 antagonistic activity in rat <i>vas deferens</i> bioassay (pA ₂) ^e	8.1	n.a.

^a For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs

^b Displacement of radiolabelled NPY from SMS-KAN cells expressing human NPY2R¹

^c Displacement of radiolabelled NPY from Y2R binding sites in rabbit kidney membrane preparations³

^d Displacement of radiolabelled ligands binding to HEK 293 cells transfected with rat Y1, Y2, Y4, and Y5 receptor cDNA, respectively. For details see lit⁴

^e Alteration of NPY-induced inhibition of the twitch response in electrically stimulated rat *vas deferens* preparations by an Y2 antagonist⁴

In vitro DMPK and CMC parameters

BIIE0246 is a large and flexible peptidomimetic molecule with rather poor drug-like properties, displaying low permeability, high Plasma Protein Binding and moderate microsomal stability. Accordingly, for *in vivo* investigations BIIE0246 is best administered via parenteral routes.

PROBE NAME / NEGATIVE CONTROL	BIIE0246	BIIE0212
logD @ pH 2	2.2	1.5
Solubility @ pH 2.2 / pH 4.4 / pH 6.8 [µg/mL]	206 / 26 / 20	166 / 82 / n.a.
PAMPA permeability [$\cdot 10^{-6} \text{ cm} \cdot \text{s}^{-1}$]	0.005	0.01
Caco-2 permeability AB @ pH 7.4 [$\cdot 10^{-6} \text{ cm} \cdot \text{s}^{-1}$]	<0.86	3.5
Caco-2 efflux ratio	>1.1	1.3
MDCK permeability P _{appAB} @ 1µM [$\cdot 10^{-6} \text{ cm} \cdot \text{s}^{-1}$]	P _{a-b} : <0.2	P _{a-b} : <0.23

MDCK efflux ratio	>1.1	>1.1
Microsomal stability (human/mouse/rat) [% Q _H]	62 / 40 / 66	74 / 61 / 79
Hepatocyte stability (human/mouse/rat) [% Q _H]	5 / 26 / 38	15 / 61 / 54
Plasma Protein Binding (human/rat) [%]	99.0 / 99.4	99.1 / 99.4
hERG (IC ₅₀) [μM]	> 0.1	> 0.3
CYP 3A4 (IC ₅₀) [μM]	3.2	8.6
CYP 2C8 (IC ₅₀) [μM]	10.9	18.9
CYP 2C9 (IC ₅₀) [μM]	> 50.0	46.7
CYP 2C19 (IC ₅₀) [μM]	> 50.0	> 50.0
CYP 2D6 (IC ₅₀) [μM]	20.4	24.1

In vivo pharmacology

BIIE0246 was used as a subtype selective pharmacological tool in several *in vivo* studies to investigate the (patho-) physiological role of Y2 receptor modulation in various tissues – including from the brain¹⁰⁻¹⁵. However, the duration of action after i.v. or i.p. application is rather short (in mice a half-life of < 3h was estimated¹⁵). Central availability of BIIE0246 after systemic administration was shown to be limited (brain to plasma ratio: 0.2 % 30 min after i.p. dosing¹⁶); hence, for the study of central Y2R mediated effects BIIE0246 was administered intrathecally or injected directly into the brain region of interest¹¹.

Negative control

BIIE0212 is a close analogue from the same series of L-argininamides with similar physicochemical properties but with a more than 400-fold lower affinity towards the Y2 receptor³.




Figure 3: BIIE0212 which serves as a negative control

Selectivity

BIIE0246 features an excellent subtype selectivity as indicated by a >600 fold lower affinity in rat Y1, Y4 and Y5 radioligand binding assays. No bioactivity was seen in a panel of 60 other receptor types or enzymes¹. Screening against a panel of 40 brain relevant targets revealed submicromolar affinity only in case of the α 1A adrenergic receptor and the μ - and κ -opioid receptors¹⁶.

SELECTIVITY DATA AVAILABLE	BIIE0246	BIIE0212
SafetyScreen44™ with kind support of  eurofins	Yes	Yes
Invitrogen®	No	No
DiscoverX®	No	No
Dundee	No	No

Reference molecules

Structurally BIIE0246 is an L-arginine derivative mimicking the C-terminal RQRYamide motif of the endogenous signal peptides NPY and peptide YY (PYY).

JNJ-5207787¹⁷, JNJ31020028^{18,19}, [3H]UR-PLN196²⁰, Cpd. 36 (GSK)²¹, Cpd. 2 (GSK)²², CYM 9484 and CYM 9552²³, SF-11²⁴, ML052²⁵, and ML075²⁵ can serve as reference molecules.

Supplementary data

Selectivity data can be downloaded free of charge from [opnMe](#).

References

1. Doods H., Gaida W., Wieland H. A., Dollinger H., Schnorrenberg G., Esser F., Engel W., Eberlein W., Rudolf K. BIIE0246: A Selective and High Affinity Neuropeptide Y Y2 Receptor Antagonist *Eur J Pharmacol* **1999**, 384 (2–3), R3. [DOI: 10.1016/s0014-2999\(99\)00650-0](#), [PubMed: 10611450](#).
2. Burkert K., Zellmann T., Meier R., Kaiser A., Stichel J., Meiler J., Mittapalli G. K., Roberts E., Beck-Sickinger A. G. A Deep Hydrophobic Binding Cavity Is the Main Interaction for Different Y2R Antagonists *Chemmedchem* **2017**, 12 (1), 75–85. [DOI: 10.1002/cmdc.201600433](#), [PubMed: 27874262](#).

3. Dollinger H., Doods H., Esser F., Gaida W., Mihm G., Rudolf K., Schnorrenberg G. Neue substituierte Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen **1999**, DE19816929. [Patent: DE19816929A1](#).
4. Dumont Y., Cadieux A., Doods H., Pheng L. H., Abounader R., Hamel E., Jacques D., Regoli D., Quirion R. BIIE0246, a Potent and Highly Selective Non-Peptide Neuropeptide Y Y2 Receptor Antagonist *Brit J Pharmacol* **2000**, 129 (6), 1075–1088. [DOI: 10.1038/sj.bjp.0703162](#), [PubMed: 10725255](#).
5. Berglund M. M., Fredriksson R., Salaneck E., Larhammar D. Reciprocal Mutations of Neuropeptide Y Receptor Y2 in Human and Chicken Identify Amino Acids Important for Antagonist Binding *Febs Lett* **2002**, 518 (1–3), 5–9. [DOI: 10.1016/s0014-5793\(02\)02534-6](#), [PubMed: 11997008](#).
6. Ziemek R., Brennauer A., Schneider E., Cabrele C., Beck-Sickinger A. G., Bernhardt G., Buschauer A. luorescence- and Luminescence-Based Methods for the Determination of Affinity and Activity of Neuropeptide Y2 Receptor Ligands *Eur J Pharmacol* **2006**, 551 (1–3), 10–18. [DOI: 10.1016/j.ejphar.2006.08.075](#), [PubMed: 17027743](#).
7. Pluym N., Brennauer A., Keller M., Ziemek R., Pop N., Bernhardt G., Buschauer A. Application of the Guanidine-Acylguanidine Bioisosteric Approach to Argininamide-Type NPY Y2 Receptor Antagonists *Chemmedchem* **2011**, 6 (9), 1727–1738. [DOI: 10.1002/cmdc.201100241](#), [PubMed: 21692185](#).
8. Dautzenberg F. M., Higelin J., Pflieger P., Neidhart W., Guba W. Establishment of robust functional assays for the characterization of neuropeptide Y (NPY) receptors: identification of 3-(5-benzoyl-thiazol-2-ylamino)-benzonitrile as selective NPY type 5 receptor antagonist *Neuropharmacology*. **2005**, 48, 1043–55. [DOI: 10.1016/j.neuropharm.2005.01.020](#), [PubMed: 15857631](#).
9. Pop N., Igel P., Brennauer A., Cabrele C., Bernhardt G., Seifert R., Buschauer A. Functional Reconstitution of Human Neuropeptide Y (NPY) Y2 and Y4 Receptors in Sf9 Insect Cells *J Recept Sig Transd* **2011**, 31 (4), 271–285. [DOI: 10.3109/10799893.2011.583253](#), [PubMed: 21745157](#).
10. Malmström R. E., Lundberg J. O. N., Weitzberg E. Autoinhibitory Function of the Sympathetic Prejunctional Neuropeptide Y Y2 Receptor Evidenced by BIIE0246 *Eur J Pharmacol* **2002**, 439 (1–3), 113–119. [DOI: 10.1016/s0014-2999\(02\)01371-7](#), [PubMed: 11937100](#).
11. Abbott C. R., Small C. J., Kennedy A. R., Neary N. M., Sajedi A., Ghatei M. A., Bloom S. R. Blockade of the Neuropeptide Y Y2 Receptor with the Specific Antagonist BIIE0246 Attenuates the Effect of Endogenous and Exogenous Peptide YY(3-36) on Food

- Intake *Brain Res* **2005**, 1043 (1–2), 139–144. [DOI: 10.1016/j.brainres.2005.02.065](https://doi.org/10.1016/j.brainres.2005.02.065), [PubMed: 15862527](https://pubmed.ncbi.nlm.nih.gov/15862527/).
12. Malmstrom R. E. Vascular Pharmacology of BII0246, the First Selective Non-Peptide Neuropeptide Y Y2 Receptor Antagonist, in Vivo *Brit J Pharmacol* **2001**, 133 (7), 1073–1080. [DOI: 10.1038/sj.bjpp.0704171](https://doi.org/10.1038/sj.bjpp.0704171), [PubMed: 11487518](https://pubmed.ncbi.nlm.nih.gov/11487518/).
13. Rimondini R., Thorsell A., Heilig M. Suppression of Ethanol Self-Administration by the Neuropeptide Y (NPY) Y2 Receptor Antagonist BII0246: Evidence for Sensitization in Rats with a History of Dependence *Neurosci Lett* **2005**, 375 (2), 129–133. [DOI: 10.1016/j.neulet.2004.10.084](https://doi.org/10.1016/j.neulet.2004.10.084), [PubMed: 15670655](https://pubmed.ncbi.nlm.nih.gov/15670655/).
14. Scott V., Kimura N., Stark J. A., Luckman S. M. Intravenous Peptide YY3-36 and Y2 Receptor Antagonism in the Rat: Effects on Feeding Behavior *J Neuroendocrinol* **2005**, 17 (7), 452–457. [DOI: 10.1111/j.1365-2826.2005.01330.x](https://doi.org/10.1111/j.1365-2826.2005.01330.x), [PubMed: 15946163](https://pubmed.ncbi.nlm.nih.gov/15946163/).
15. Ailanen L., Vähätalo L. H., Salomäki-Myftari H., Mäkelä S., Orpana W., Ruohonen S. T., Savontaus E. Peripherally Administered Y2-Receptor Antagonist BII0246 Prevents Diet-Induced Obesity in Mice with Excess Neuropeptide Y, but Enhances Obesity in Control Mice *Front Pharmacol* **2018**, 9, 319/1. [DOI: 10.3389/fphar.2018.00319](https://doi.org/10.3389/fphar.2018.00319), [PubMed: 29674968](https://pubmed.ncbi.nlm.nih.gov/29674968/).
16. Bonaventure P., Nepomuceno D., Mazur C., Lord B., Rudolph D. A., Jablonowski J. A., Carruthers N. I., Lovenberg T. W. Characterization of N-(1-Acetyl-2,3-Dihydro-1H-Indol-6-yl)-3-(3-Cyano-Phenyl)-N-[1-(2-Cyclopentyl-Ethyl)-Piperidin-4yl]Acrylamide (JNJ-5207787), a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor *J Pharmacol Exp Ther* **2004**, 308 (3), 1130–1137. [DOI: 10.1124/jpet.103.060459](https://doi.org/10.1124/jpet.103.060459), [PubMed: 14617685](https://pubmed.ncbi.nlm.nih.gov/14617685/).
17. Shoblock J. R., Welty N., Nepomuceno D., Lord B., Aluisio L., Fraser I., Motley S. T., Sutton S. W., Morton K., Galici R., Attack J. R., Dvorak L., Swanson D. M., Carruthers N. I., Dvorak C., Lovenberg T. W., Bonaventure P. In Vitro and in Vivo Characterization of JNJ-31020028 (N-(4-{4-[2-(Diethylamino)-2-Oxo-1-Phenylethyl]Piperazin-1-yl}-3-Fluorophenyl)-2-Pyridin-3-ylbenzamide), a Selective Brain Penetrant Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor *Psychopharmacology* **2009**, 208 (2), 265. [DOI: 10.1007/s00213-009-1726-x](https://doi.org/10.1007/s00213-009-1726-x), [PubMed: 19953226](https://pubmed.ncbi.nlm.nih.gov/19953226/).
18. Swanson D. M., Wong V. D., Jablonowski J. A., Shah C., Rudolph D. A., Dvorak C. A., Seierstad M., Dvorak L. K., Morton K., Nepomuceno D., Attack J. R., Bonaventure P., Lovenberg T. W., Carruthers N. I. The Discovery and Synthesis of JNJ 31020028, a Small Molecule Antagonist of the Neuropeptide Y Y2 Receptor *Bioorg Med Chem Lett* **2011**, 21 (18), 5552–5556. [DOI: 10.1016/j.bmcl.2011.06.136](https://doi.org/10.1016/j.bmcl.2011.06.136), [PubMed: 21802951](https://pubmed.ncbi.nlm.nih.gov/21802951/).

19. Pluym N., Baumeister P., Keller M., Bernhardt G., Buschauer A. [3H]UR-PLN196: A Selective Nonpeptide Radioligand and Insurmountable Antagonist for the Neuropeptide Y Y2 Receptor *Chemmedchem* **2013**, 8 (4), 587–593. DOI: [10.1002/cmdc.201200566](https://doi.org/10.1002/cmdc.201200566), PubMed: [23361914](https://pubmed.ncbi.nlm.nih.gov/23361914/).
20. Lunniss G. E., Barnes A. A., Barton N., Biagetti M., Bianchi F., Blowers S. M., Caberlotto L., Emmons A., Holmes I. P., Montanari D., Norris R., Walters D. J., Watson S. P. The Identification and Optimisation of Novel and Selective Diamide Neuropeptide Y Y2 Receptor Antagonists *Bioorg Med Chem Lett* **2009**, 19 (15), 4022–4025. DOI: [10.1016/j.bmcl.2009.06.035](https://doi.org/10.1016/j.bmcl.2009.06.035), PubMed: [19581086](https://pubmed.ncbi.nlm.nih.gov/19581086/).
21. Lunniss G. E., Barnes A. A., Barton N., Biagetti M., Bianchi F., Blowers S. M., Caberlotto L., Emmons A., Holmes I. P., Montanari D., Norris R., Puckey G. V., Walters D. J., Watson S. P., Willis J. The Identification of a Series of Novel, Soluble Non-Peptidic Neuropeptide Y Y2 Receptor Antagonists *Bioorg Med Chem Lett* **2010**, 20 (24), 7341–7344. DOI: [10.1016/j.bmcl.2010.10.065](https://doi.org/10.1016/j.bmcl.2010.10.065), PubMed: [21074426](https://pubmed.ncbi.nlm.nih.gov/21074426/).
22. Mittapalli G. K., Vellucci D., Yang J., Toussaint M., Brothers S. P., Wahlestedt C., Roberts E. Synthesis and SAR of Selective Small Molecule Neuropeptide Y Y2 Receptor Antagonists *Bioorg Med Chem Lett* **2012**, 22 (12), 3916–3920. DOI: [10.1016/j.bmcl.2012.04.107](https://doi.org/10.1016/j.bmcl.2012.04.107), PubMed: [22607676](https://pubmed.ncbi.nlm.nih.gov/22607676/).
23. Domin H., Piergies N., Pięta E., Wyska E., Pochwat B., Wlaź P., Śmiałowska M., Paluszkiewicz C., Szewczyk B. Characterization of the Brain Penetrant Neuropeptide Y Y2 Receptor Antagonist SF-11 *Acs Chem Neurosci* **2019**, 10 (8), 3454–3463. DOI: [10.1021/acscchemneuro.9b00082](https://doi.org/10.1021/acscchemneuro.9b00082), PubMed: [1267743](https://pubmed.ncbi.nlm.nih.gov/1267743/).